ReviewSeminars in perinatology2013
An update on pharmacologic approaches to bronchopulmonary dysplasia.
Review in Seminars in perinatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Superoxide dismutase for bronchopulmonary dysplasia in preterm infants.The Cochrane database of systematic reviews · 2023Pooled it
- Pulmonary outcomes in adults with a history of Bronchopulmonary Dysplasia differ from patients with asthma.Respiratory research · 2019Trial
- The Inflammatory Nexus of Bronchopulmonary Dysplasia: From Molecular Pathways to Precision Therapeutics.Mediators of inflammation · 2026Review
- Development of CPAP Overlay Interfaces for Efficient Administration of Aerosol Surfactant Therapy to Preterm Infants.AAPS PharmSciTech · 2025Article
- Large airway T cells in adults with former bronchopulmonary dysplasia.Respiratory research · 2024Article
- Association of time of first corticosteroid treatment with bronchopulmonary dysplasia in preterm infants.Pediatric pulmonology · 2021Article
- Early administration of amino acids with different doses in low birth weight premature infants.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2020Article
- Respiratory Medications in Infants <29 Weeks during the First Year Postdischarge: The Prematurity and Respiratory Outcomes Program (PROP) Consortium.The Journal of pediatrics · 2019Observational
- Preventing bronchopulmonary dysplasia: new tools for an old challenge.Pediatric research · 2019Review
- Article
- Should we still use vitamin A to prevent bronchopulmonary dysplasia?Journal of perinatology : official journal of the California Perinatal Association · 2016Review
- Nitric oxide in paediatric respiratory disorders: novel interventions to address associated vascular phenomena?Therapeutic advances in cardiovascular disease · 2016Review
- Quantitative Magnetic Resonance Imaging of Bronchopulmonary Dysplasia in the Neonatal Intensive Care Unit Environment.American journal of respiratory and critical care medicine · 2015Article
- Use of inhaled corticosteroids for the prevention and/or treatment of bronchopulmonary dysplasia in preterm infants: a systematic review protocol.Systematic reviews · 2015Article
- Drug therapy for the prevention and treatment of bronchopulmonary dysplasia.Frontiers in pharmacology · 2015Review
- Antenatal use of bosentan and/or sildenafil attenuates pulmonary features in rats with congenital diaphragmatic hernia.World journal of pediatrics : WJP · 2014Article
- Anti-inflammatory actions of endogenous and exogenous interleukin-10 versus glucocorticoids on macrophage functions of the newly born.Journal of perinatology : official journal of the California Perinatal Association · 2014Article
- Lung stem and progenitor cells in tissue homeostasis and disease.Current topics in developmental biology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Bronchopulmonary dysplasia (BPD) is the most prevalent long-term morbidity in surviving extremely preterm infants and is linked to increased risk of reactive airways disease, pulmonary hypertension, post-neonatal mortality, and adverse neurodevelopmental outcomes. BPD affects approximately 20% of premature newborns, and up to 60% of premature infants born before completing 26 weeks of gestation. It is characterized by the need for assisted ventilation and/or supplemental oxygen at 36 weeks postmenstrual age. Approaches to prevention and treatment of BPD have evolved with improved understanding of its pathogenesis. This review will focus on recent advancements and detail current research in pharmacotherapy for BPD. The evidence for both current and potential future experimental therapies will be reviewed in detail. As our understanding of the complex and multifactorial pathophysiology of BPD changes, research into these current and future approaches must continue to evolve.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.